• Donate now
  • Monthly Giving
  • Support Calendar – What’s On
  • Contact us
  • About us
    • Our vision
    • What we do
    • Our Impact
    • Our team
    • Work for us
    • Volunteer
    • The DMD Registry
  • Celebrating our Action Duchenne Champions
  • Get Support
    • Recently diagnosed
    • Group Counselling Programme
    • Connect with others
      • Online support sessions
      • Support for 14-25 yrs ‘Yes I Can’
      • Support for 8-14 yrs ‘Turning Point’
    • Science on Tour 2023
    • Schools
    • Siblings
    • End of Life & Bereavement
  • International Conference
    • 2022 Recordings
  • News, Blogs & Webinars
    • News
    • Blogs
    • Webinar recordings
  • Challenge 79
  • Support Us
    • Make a Pledge
  • Shop
  •  0 items - Free
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to primary sidebar
  • Skip to footer

Before Header

  • BECOME A MEMBER
  • SHOP
  • My account
  •  0 items - Free

Action Duchenne

Header Right

  • About Us
    • Our vision
    • Our Strategy
    • What we do
    • Our Impact
    • Our team
    • Work for us
      • Volunteer for us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Mental Health Awareness Week 2025
    • Science on Tour
    • Support Calendar – What’s On
    • Support for you and your family
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
      • Open Space
      • Group Counselling Programme
    • Recently diagnosed
    • Connect with others
    • Support for 8-14 yrs ‘Turning Point’
    • Support for 14-25 yrs ‘Yes I Can’
    • Schools
    • Siblings
    • End of Life and Bereavement
  • AD Annual International Conference
    • SAVE THE DATE for the Action Duchenne Annual International Conference 2025
    • Highlights from the Annual Action Duchenne Annual International 2024
    • Annual International Conference 2023 Video Recordings
    • Annual International Conference 2022 Recordings
      • Adults with Duchenne
      • Growing up with Duchenne
      • The Duchenne Journey
      • What is new in Duchenne research?
  • News, Webinars and Blogs
    • News
    • Webinar Series 2025
      • Webinar Series 2025
      • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Blogs
  • Support Us
    • Help Make a Life Beyond Duchenne Possible – Every Month
    • Fundraising Events and Challenges
    • Take on a challenge for Duchenne
    • Shop
You are here: Home / News / Exon skipping news / Golodirsen gains conditional approval in US
Golodirsen gains conditional approval in US

Golodirsen gains conditional approval in US

December 16, 2019 by Neil

Sarepta Therapeutics has announced that the FDA (the medicines regular in the US) has granted accelerated approval to golodirsen. 

Golodirsen, or Vyondys 53 as it will be known, is an exon skipping drug designed to skip exon 53 of the dystrophin gene. It has the potential to treat approximately 8% of people living with Duchenne. 

Trial data showed that Vyondys increased dystrophin production in the muscles of those who received it. Accelerated approval means the company can make the drug available while carrying out further trials to collect more data about the drug’s effectiveness. 

This news is particularly exciting for us at Action Duchenne – the first trials of Vyondys 53 took place as part of the Skip-NMD project that we were heavily involved with alongside MDUK and PPMD Onlus. The project was an EU-funded collaborative effort between pharma, clinicians, researchers and charities to develop and test a drug to skip exon 53 of the dystrophin gene. 

Because each country has its own medicines regulator, this decision won’t make the drug available to people outside the US. However, Sarepta are engaging with the European regulator to understand what data would be needed to support an application for marketing here. We hope the ongoing trials will provide the data required and we’ll be working with Sarepta to represent our families across the UK.

Share this:

Category: Exon skipping news, NewsTag: Action Duchenne, clinical trial, exon skipping, research

Previous Post: « Wave halts development of exon skipping drugs
Next Post: Sarepta Therapeutics and Roche to partner on gene therapy »

Primary Sidebar

From our community

Mental Health Awareness Week: Alex’s Journal

Written By Alex Berbank 15 Minutes a Day I’ve really enjoyed getting into the frame of mind to look at my mental health. Before this week I wasn’t quite sure what to expect. My ideas of what looking at my own mental health would look like weren’t accurate. I thought there would be more softly …

Mental Health Awareness Week: Alex’s Journal

Mental Health Awareness Week Journal, Written by Alex Berbank Watch Alex’s Vlog for Mental Health Awareness Week Thursday’s Update: Meditation and Mindfulness So, to this point this week has been great. I’ve actually taken to the focus on my mental health and self improvement thing quite well and I hope I’ll keep these new ideas …

Mental Health Awareness Week – Alex’s Blog

Written by Alex Berbank Wednesday: Getting Into The Swing of Things The changes yesterday were about removing phones from certain times in the house, namely when eating, before bed and when me and my Fiancee are in the house together. The idea was that we would be more connected, talk more and just be a …

Footer

Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS

07535 498 506
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852

Like most websites we use cookies to deliver a personalised service. To use the website as intended please accept cookies.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT